Two years after an FDA rejection sent Delcath Systems spiraling, the company has reached an agreement with the regulatory agency to move its once-rejected drug-device combo forward.
The biotech announced Jan. 19 that it has established a special protocol assessment (SPA) for its Phase III trial of...


![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://insights.citeline.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

